MLL3 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
Dual inhibitor of histone methyltransferases (HMTs) G9a and GLP, influencing histone methylation and chromatin remodeling. UNC1999 can potentially modulate MLL3 activity by affecting the epigenetic landscape and histone modifications related to MLL3 function. | ||||||
9-[5-Deoxy-5-[[cis-3-[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]ethyl]cyclobutyl](1-methylethyl)amino]-β-D-ribofuranosyl]-9H-purin-6-amine | 1380288-87-8 | sc-500607 | 50 mg | $13500.00 | ||
DOT1L (DOT1-like) inhibitor targeting histone H3 lysine 79 (H3K79) methylation. EPZ-5676 can influence MLL3 indirectly by affecting a shared pathway involved in histone methylation, potentially modulating MLL3-dependent gene expression. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $90.00 $238.00 $300.00 | ||
Enhancer of zeste homolog 2 (EZH2) inhibitor influencing histone methylation. GSK126 targets EZH2, potentially affecting the trimethylation of histone H3 lysine 27 (H3K27) and indirectly modulating MLL3 activity through epigenetic regulation. | ||||||
(S)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide | 202590-98-5 | sc-501130 | 2.5 mg | $330.00 | ||
Bromodomain and extraterminal (BET) protein inhibitor affecting chromatin remodeling. OTX015 targets BET proteins, potentially modulating MLL3 activity by influencing the recruitment of MLL3 to specific chromatin regions and altering histone modifications. | ||||||
SGC-CBP30 | 1613695-14-9 | sc-473871 sc-473871A | 5 mg 10 mg | $178.00 $338.00 | ||
CREB-binding protein (CBP) and p300 bromodomain inhibitor affecting histone acetylation. SGC-CBP30 can modulate MLL3 indirectly by influencing histone acetylation patterns and chromatin structure associated with MLL3-dependent gene regulation. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $148.00 $452.00 | 1 | |
EZH2 inhibitor affecting histone methylation. GSK343 targets EZH2, potentially influencing MLL3 indirectly through alterations in the trimethylation of histone H3 lysine 27 (H3K27) and the epigenetic regulation of shared target genes. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
Histone acetyltransferase (HAT) inhibitor targeting p300/CBP-associated factor (PCAF). C646 can potentially modulate MLL3 activity by affecting histone acetylation patterns associated with MLL3-dependent gene expression and chromatin remodeling. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
BET protein inhibitor affecting chromatin structure. JQ1 targets BET proteins, potentially influencing MLL3 activity by modulating the recruitment of MLL3 to specific chromatin regions and altering histone modifications associated with MLL3-dependent processes. | ||||||
CPI-203 | 1446144-04-2 | sc-501599 | 1 mg | $170.00 | ||
BET protein inhibitor influencing chromatin structure. CPI-203 targets BET proteins, potentially modulating MLL3 activity by affecting the recruitment of MLL3 to specific chromatin regions and altering histone modifications associated with MLL3-dependent processes. | ||||||
UNC0638 | 1255580-76-7 | sc-397012 | 10 mg | $315.00 | ||
G9a and GLP histone methyltransferase inhibitor affecting histone methylation. UNC0638 can potentially modulate MLL3 activity by influencing the epigenetic landscape and histone modifications associated with MLL3-dependent gene regulation. | ||||||